Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

Key Takeaways Editas posts a Q3 loss of $0.28 per share, beating estimates and improving from last year's $0.75 loss.Revenues jump to $7.5M, driven by milestone payment recognition from the Bristol Myers collaboration.Editas designates EDIT-401 as its lead in vivo gene-editing therapy targeting LDL cholesterol reduction.Editas Medicine (EDIT) reported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss o ...